학술논문
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
Article
Author
Monk, Phillip D; Marsden, Richard J; Tear, Victoria J; Brookes, Jody; Batten, Toby N; Mankowski, Marcin; Gabbay, Felicity J; Davies, Donna E; Holgate, Stephen T; Ho, Ling-Pei; Clark, Tristan; Djukanovic, Ratko; Wilkinson, Tom M A; Crooks, Michael G; Dosanjh, Davinder PS; Siddiqui, Salman; Rahman, Najib M; Smith, Jacklyn A; Horsley, Alexander; Harrison, Timothy W; Saralaya, Dinesh; McGarvey, Lorcan; Watson, Alastair; Foster, Edmund; Fleet, Adam; Singh, Dave; Hemmings, Sophie; Aitken, Sandra; Dudley, Sarah; Beegan, Rona; Thompson, Angela; Rodrigues, Pedro MB
Source
The Lancet Respiratory Medicine; February 2021, Vol. 9 Issue: 2 p196-206, 11p
Subject
Language
ISSN
22132600; 22132619
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19.